Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: Biologic rationale and implications for stem-cell research in breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages

  Moulder, Stacy ^a   Moroney, John ^a   Helgason, Thorunn ^a   Wheler, Jennifer ^a   Booser, Daniel ^a   Albarracin, Constance ^a   Morrow, Phuong K ^a   Koenig, Kimberly ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IXABEPILONE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMSIROLIMUS; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURGERY; CLINICAL ARTICLE; CODON; CONGESTIVE HEART FAILURE; DEPRESSION; DNA SEQUENCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE BIOPSY; MASTECTOMY; METAPLASTIC BREAST CARCINOMA; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEINURIA; SENTINEL LYMPH NODE; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DOXORUBICIN; FEMALE; HUMANS; METAPLASIA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIROLIMUS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 79960127513     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0604     Document Type: Article

References (23)

1. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 21:1142-1150, 1990
2. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast: I. Matrix-producing carcinoma. Hum Pathol 20:628-635, 1989
3. Wargotz ES, Deos PH, Norris HJ: Metaplastic carcinomas of the breast: II. Spindle cell carcinoma. Hum Pathol 20:732-740, 1989
4. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast: III. Carcinosarcoma. Cancer 64:1490-1499, 1989
5. Wargotz ES, Norris HJ: Metaplastic carcinomas of the breast: IV. Squamous cell carcinoma of ductal origin. Cancer 65:272-276, 1990
6. Tse GM, Tan PH, Putti TC, et al: Metaplastic carcinoma of the breast: A clinicopathological review. J Clin Pathol 59:1079-1083, 2006 (Pubitemid 44570331)
7. Oberman HA: Metaplastic carcinoma of the breast: A clinicopathologic study of 29 patients. Am J Surg Pathol 11:918-929, 1987
8. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
9. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res 69:4116-4124, 2009
10. Hennessy BT, Giordano S, Broglio K, et al: Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 17:605-613, 2006
11. Jung SY, Kim HY, Nam BH, et al: Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 120:627-637, 2010
12. Okada N, Hasebe T, Iwasaki M, et al: Metaplastic carcinoma of the breast. Hum Pathol 41:960-970, 2010
13. Luini A, Aguilar M, Gatti G, et al: Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: The experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 101:349-353, 2007 (Pubitemid 46169889)
14. Rayson D, Adjei AA, Suman VJ, et al: Metaplastic breast cancer: Prognosis and response to systemic therapy. Ann Oncol 10:413-419, 1999 (Pubitemid 29236418)
15. Creighton CJ, Li X, Landis M, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820-13825, 2009
16. Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82, 2007 (Pubitemid 46054518)
17. Bellino R, Arisio R, D'Addato F, et al: Metaplastic breast carcinoma: Pathology and clinical outcome. Anticancer Res 23:669-673, 2003 (Pubitemid 36358470)
18. Kochhar R, Howard EM, Umbreit JN, et al: Metaplastic breast carcinoma with squamous differentiation: Molecular and clinical analysis of six cases. Breast J 11:367-369, 2005 (Pubitemid 41726048)
19. Zhou J, Wulfkuhle J, Zhang H, et al: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104:16158-16163, 2007 (Pubitemid 350099378)
20. Mungamuri SK, Yang X, Thor AD, et al: Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Res 66:4715-4724, 2006
21. Pantuck AJ, Zeng G, Belldegrun AS, et al: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641-4652, 2003 (Pubitemid 37323266)
22. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549-5554, 2006 (Pubitemid 43927103)
23. Huynh H, Chow PK, Palanisamy N, et al: Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49:52-60, 2008